LONDON, June 13, 2018 - (ACN Newswire) - LEH Pharma Ltd, the leading provider of novel ocular implants for macular disorders today announces the appointment of Professor Robert Devenyi and Dr Sadeer Hannush to its Scientific Advisory Board (SAB). The SAB, comprised of world-leading experts in ophthalmology, will work closely with LEH Pharma's senior management team to advance the Company's commercialisation of the EyeMax lens, a unique, proven and patented product marketed internationally for the treatment of age-related macular degeneration (AMD).
Professor Robert G Devenyi MD, MBA, FRCSC, FACS, said: "The calibre of the individuals participating on this SAB is in itself an excellent validation of LEH Pharma and its technology. LEH has assembled a team with wide-ranging, high quality experience relevant to LEH Pharma's business activities and objectives, and reflective of the jurisdictions the company is targeting in the immediate to medium term."
"The guidance of this world-leading group of surgeons and ophthalmology specialists is proving invaluable as we continue the international roll-out of the ground breaking EyeMax lens, which we believe has the potential to improve the quality of life of millions of patients with AMD worldwid," said Dr Bobby Qureshi, Founder and CEO of LEH Pharma. "We welcome Professor Devenyi and Dr Hannush to the SAB look forward to drawing on their insights and extensive expertise as we move forward with the commercialisation of this exciting product."
The members of the LEH Pharma Scientific Advisory Board include:
Professor Robert G Devenyi MD, MBA, FRCSC, FACS Professor of Ophthalmology and Vision Sciences at the University of Toronto, Ophthalmologist-in-Chief and Director of Retinal Services at the Donald K. Johnson Eye Institute at the University Health Network.
Professor Pablo Artal, Professor of Optics at the University of Murcia, recipient of the "Edwin H. Land Medal" for scientific contributions to the advancement of diagnostic and correction alternatives in visual optics.
Professor Dr. med. Fritz H Hengerer, Professor of Ophthalmology and Deputy Medical Director at the University Eye Clinic Heidelberg in Germany.
Dr Federico Badala MD, specialist eye surgeon practicing in Catania, Milan and Rome, International Fellow in Glaucoma at the Jules Stein Eye Institute of the University of California Los Angeles (UCLA).
Dr Sadeer B. Hannush MD, Attending Surgeon at the Cornea Service at Wills Eye Hospital, Department of Ophthalmology at Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania.
Dr Alain Saad MD, attending physician in the Anterior Segment and Refractive Surgery Department at the Rothschild Foundation, Paris, Assistant Professor in the Cornea and Refractive Surgery Division of the Department of Ophthalmology, American University of Beirut Medical Center, Beirut, Lebanon.
Dr Scott Robbie MBBS BSc (Hons) GMP FRCOphth PhD, Consultant ophthalmic surgeon at Guy's and St. Thomas' NHS Foundation Trust in London, lecturer at the National Institute for Health Research Clinical Lectureship.
For more information, please contact:
LEH Pharma Ltd
Dr Bobby Qureshi
+ 44 (0) 20 7060 2763
Consilium Strategic Communications
Mary-Jane Elliott, Ivar Milligan, Chris Welsh
+44 (0) 20 3709 5700
Notes for editors:
About LEH Pharma
LEH Pharma is a leading provider of revolutionary ocular implants for macular disorders. Its disruptive lens technology, which is unique, proven and patented, is currently marketed internationally for the treatment of stable wet and dry AMD. The Company was formed in 2011 by a group of pioneering surgeons, and is supported by a network of world-leading ophthalmologists and scientists. For more information, please visit LEH Pharma's website at www.lehpharma.com
EyeMax is a revolutionary breakthrough for AMD sufferers and is the only adequate solution for the treatment of both the stable wet and dry form of the condition. EyeMax can be used in both eyes and can be applied fast and easily. The innovative technology and unique optics of the EyeMax lens diverts images away from the damaged part of the eye and enhances them to the healthy parts. Advantages of the product are safer surgery, ease of implantation and significant improvement of vision for patients. Currently, the only other option available for patients results in sub-optimal vision and remaining AMD symptoms. EyeMax is CE-marked in Europe and is exploring FDA approval in the US.
About age related macular degeneration (AMD)
LEH Pharma's EyeMax product is aimed at improving the quality of life of patients with AMD, the western world's biggest cause of blindness and the greatest unmet need in ophthalmology. AMD is a disorder affecting the central part of the retina, causing changes to central vision and making everyday tasks difficult.
EyeMax is aimed at two main patient populations: those who require cataract surgery - for whom there is a 29-55% chance of being suitable for an AMD lens after the age of 70 and the non-cataract population including patients with AMD prior to cataract surgery or sufferers of other macular diseases such as diabetic eye disease.
 Published data from several European centres supports the effectiveness of EyeMax and can be found on the website here (www.iolamd.com/clinical-data). Most recently the European Journal of Ophthalmology found EyeMax safe and observed improvements after surgery above those of standard implants.
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.